目的 分析辽宁省肿瘤医院2020—2022年免疫检查点抑制剂的使用情况以及变化趋势，为规范其管理及临床合理使用提供参考。方法 收集2020—2022年辽宁省肿瘤医院免疫检查点抑制剂使用数据，分析销售金额、用药频度（DDDs）、限定日费用（DDC）以及排序比（B/A）。结果 2020—2022年免疫检查点抑制剂销售金额大幅增长。帕博利珠单抗和替雷利珠单抗使用金额较大，排名靠前。2022年新增的品种（阿替利珠单抗、卡度尼利单抗、赛帕利单抗、斯鲁利单抗、舒格利单抗、恩沃利单抗）销售金额排名靠后。替雷利珠单抗的DDDs近3年大幅增加。卡度尼利单抗、度伐利尤单抗、帕博利珠单抗、纳武利尤单抗DDC值偏高，且B/A＜1。信迪利单抗、替雷利珠单抗、卡瑞利珠单抗、特瑞普利单抗DDC在2022年有大幅度的下降，DDC值较低，且B/A＞1。结论 2020—2022年辽宁省肿瘤医院免疫检查点抑制剂的使用总体上比较合理，但仍需进一步加强监管力度，保障患者用药的安全、有效和经济。

Objective To analyze the usage and variation tendency of immune checkpoint inhibitors in Liaoning Cancer Hospital and Institute from 2020 to 2022, and provide references for standardizing the management and rational application. Methods Consumption sum, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio of immune checkpoint inhibitors in Liaoning Cancer Hospital and Institute from 2020 to 2022 were analyzed statistically. Results Consumption sum and constituent ratio increased sharply year by year. Consumption sums of pembrolizumab and tislelizumab increased year by year. In 2022, consumption sums of new varieties (atezolizumab, cadonilimab, zimberelimab, serplulimab, sugemalimab, envafolimab) ranked lower. The DDDs of tislelizumab increased significantly for three consecutive years. The DDC values of cadonilimab, durvalumab, pembrolizumab and nivolumab are high, and B/A < 1. The DDC of sintilimab, toripalimab, camrelizumab, and tislelizumab decreased significantly in 2022, with a low DDC value and B/A > 1. Conclusion From 2020 to 2022, the use of immune checkpoint inhibitors in Liaoning Cancer Hospital and Institute is generally reasonable. However, it is still necessary to further strengthen supervision to ensure the safety, effectiveness and economy of treatment drugs.

R979.1

辽宁省肿瘤医院质谱课题项目（ZP202019）